An Old Adult with Alzheimer's Disease and Dementia Represented Reduced COVID‐19 Symptoms, Probably Due to Cross Impact of Drugs; A Case-Report Blended with Computational Biology Study

Abstract

Background
Studies have shown that morbidity and mortality critically increase from COVID‐19 in patients with Alzheimer’s disease and dementia. But we had an Alzheimer’s disease patient treated rapidly from COVID-19 involvement. We explore the probable cause of treatment using in-silico drug screening tools.
Case presentation
We present an 81-year-old female patient who recovered from COVID‐19 disease despite her severe dementia and Alzheimer’s disease, and unfavorable respiratory status. The patient was under medical care for ten days. She received standard COVID-19 medical care plus her drugs for Alzheimer’s disease. We found those drugs administered for Alzheimer’s disease can interact, and probably inhibit, SARS-COV-2 main protease that plays a central role in virus replication.
Conclusion
Our patient remediated from COVID-19 very well despite being at a higher risk of morbidity and mortality. However, her amnesia may help her to fight and resist respiratory distress. In addition, administered drugs for Alzheimer’s disease may interact with viral biomolecules and dwindle SARS-COV-2 replication.